Investments
172Portfolio Exits
43Funds
13About Advent Life Sciences
Advent Life Sciences is one of Europe's leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across the UK, Europe and the USA. Advent invests predominantly in early and mid-stage life sciences companies. The firm seeks to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.
Want to inform investors similar to Advent Life Sciences about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Advent Life Sciences News
Jul 6, 2023
Advent Life Sciences, the healthcare arm of Advent Venture Partners, has registered a new growth vehicle. Not a member yet? Free Membership for Qualified Investors and Industry Participants Easily Customize Content to Match Your Investment Preferences Breaking News 24/7/365 Alternative Investment Listings & LeaderBoards Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets,Presentations, Investment Mandates, Video PitchBooks & More! Company Directory AUM Accelerator Program (designed for investment managers) Over 450K+ Industry Headlines, Posts and Updates ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY.CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN.PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.THIS IS NOT A SOLICITATION FOR INVESTMENT.THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY.IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES.ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM.PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT. ALPHAMAVEN
Advent Life Sciences Investments
172 Investments
Advent Life Sciences has made 172 investments. Their latest investment was in PIC Therapeutics as part of their Series A on October 10, 2022.
Advent Life Sciences Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
10/19/2022 | Series A | PIC Therapeutics | $35M | No | 7 | |
9/15/2022 | Seed VC - II | Tridek-One | $16M | No | 7 | |
8/16/2022 | Series C - II | Moximed | No | 2 | ||
8/4/2022 | Unattributed VC - VI | |||||
6/29/2022 | Series B |
Date | 10/19/2022 | 9/15/2022 | 8/16/2022 | 8/4/2022 | 6/29/2022 |
|---|---|---|---|---|---|
Round | Series A | Seed VC - II | Series C - II | Unattributed VC - VI | Series B |
Company | PIC Therapeutics | Tridek-One | Moximed | ||
Amount | $35M | $16M | |||
New? | No | No | No | ||
Co-Investors | |||||
Sources | 7 | 7 | 2 |
Advent Life Sciences Portfolio Exits
43 Portfolio Exits
Advent Life Sciences has 43 portfolio exits. Their latest portfolio exit was MiroBio on August 04, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
8/4/2022 | Acquired | 8 | |||
10/29/2021 | IPO | Public | 10 | ||
4/1/2021 | Acquired | 3 | |||
Date | 8/4/2022 | 10/29/2021 | 4/1/2021 | ||
|---|---|---|---|---|---|
Exit | Acquired | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 8 | 10 | 3 |
Advent Life Sciences Acquisitions
2 Acquisitions
Advent Life Sciences acquired 2 companies. Their latest acquisition was Reqio on January 29, 2001.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
1/29/2001 | Series C | $6.27M | Leveraged Buyout | 1 | ||
11/28/1998 | Series B |
Date | 1/29/2001 | 11/28/1998 |
|---|---|---|
Investment Stage | Series C | Series B |
Companies | ||
Valuation | ||
Total Funding | $6.27M | |
Note | Leveraged Buyout | |
Sources | 1 |
Advent Life Sciences Fund History
13 Fund Histories
Advent Life Sciences has 13 funds, including Advent Life Sciences Fund III.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
12/6/2019 | Advent Life Sciences Fund III | Multi-Stage Venture Capital | Open | $24.8M | 2 |
10/28/2014 | Advent Life Sciences Fund II | Multi-Stage Venture Capital | Closed | $235M | 1 |
11/24/2010 | Advent Venture Life Sciences Fund V LP | Multi-Stage Venture Capital | Closed | $125M | 1 |
12/17/2004 | Advent Private Equity Fund IV LP | ||||
2/9/2001 | Advent Private Equity Fund III LP |
Closing Date | 12/6/2019 | 10/28/2014 | 11/24/2010 | 12/17/2004 | 2/9/2001 |
|---|---|---|---|---|---|
Fund | Advent Life Sciences Fund III | Advent Life Sciences Fund II | Advent Venture Life Sciences Fund V LP | Advent Private Equity Fund IV LP | Advent Private Equity Fund III LP |
Fund Type | Multi-Stage Venture Capital | Multi-Stage Venture Capital | Multi-Stage Venture Capital | ||
Status | Open | Closed | Closed | ||
Amount | $24.8M | $235M | $125M | ||
Sources | 2 | 1 | 1 |
Advent Life Sciences Team
14 Team Members
Advent Life Sciences has 14 team members, including current General Partner, Kaasim Mahmood.
Name | Work History | Title | Status |
|---|---|---|---|
Kaasim Mahmood | General Partner | Current | |
Name | Kaasim Mahmood | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | General Partner | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
